Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "Relapsing remitting" patented technology

Relapsing-remitting MS is defined as MS in which patients have relapses of MS and periods of stability in between relapses. Relapses are episodes of new or worsening symptoms not caused by fever or infection and that last more than 48 hours. In other words, a stable course is punctuated by episodes of new or worse symptoms.

Markers associated with the therapeutic efficacy of glatiramer acetate

The present invention is directed to methods and kits based, at least in part, on the identification of allele-specific responsiveness or non-responsiveness to glatiramer acetate for the treatment of immune disorders, such as relapsing-remitting multiple sclerosis. The allele-specific responsiveness or non-responsiveness is based on polymorphisms in the following genes, CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPP1 and IL-12RB2.
Owner:RAPPAPORT FAMILY INSTITUTE FOR RESEACH IN THE MEDICAL SCIENCES +2

Reduced volume formulation of glatiramer acetate and methods of administration

A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol.
Owner:TEVA PHARMA IND LTD

Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration

A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol.
Owner:TEVA PHARMA IND LTD

Rituximab induction therapy followed by glatiramer acetate therapy

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, or systemic lupus erythematosus.
Owner:TEVA PHARMA IND LTD

Low frequency glatiramer acetate therapy

InactiveCN102625657AIncreased GA treatment toleranceBiocideNervous disorderHypodermoclysisSubcutaneous injection
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Owner:YEDA RES & DEV CO LTD

N-Acetyl Glucosamine as a Biomarker of MS Disease Course

The invention provides the art with a powerful diagnostic method of distinguishing relapse-remitting MS subjects from progressive MS subjects, based on the measurement of serum concentrations of N-acetylglucosamine (GlcNAc,), for the first time enabling rapid diagnosis of the progressive form of MS. GlcNAc serum concentration can also be used to assess neurodegenerative status and MS progression in subjects suffering from MS or other neurological conditions. The methods of the invention also allow for the identification of new therapeutics for MS and other neurological conditions and also enables the personalized efficacy assessment of a potential therapy for an MS subject.
Owner:CHARITE UNIVS MEDIZIN BERLIN +2

Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

InactiveUS20150306088A1Reducing ambulatory deteriorationReduce ambulatory deteriorationBiocideNervous disorderLaquinimodHuman patient
This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.
Owner:TEVA PHARMA IND LTD

Causal therapy of diseases or conditions associated with CNS or pns demyelination

ActiveUS20120269762A1Maintain integrityAccelerates myelin repairBiocideNervous disorderActive agentRemyelination
The invention broadly relates to the use of the Active in the causal treatment of a disease caused by axonal demyelination, in which the Active maintains the integrity of myelination (for example by promoting remyelination, and / or preventing demyelination, of the axonal sheaths). The invention is particularly directed to the causal treatment of CNS demyelination diseases, for example MS, especially primary progressive MS and / or relapse remitting MS, and PNS demyelination diseases, for example Charcot-Marie-Tooth Disease. The Active of the invention may be suitably administered when a patient is in relapse (i.e. upon relapse), and be continued while the patient is in relapse, with a view to attenuating the severity of the relapse, and / or accelerating disease remission. Alternatively, the Active may be administered continuously with a view to prolonging the remission period, and / or attenuating the severity of the relapse, and / or preventing relapse. The invention also relates to the use of the Active as a treatment for symptoms of demyelination disease, especially MS, selected from vision deficits, motor control deficits, and sensation deficits.
Owner:UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN

Assay and method for predicting therapeutic efficacy of immunoglobulin therapy in individual patients with relapsing remitting multiple sclerosis (RR-MS)

A method for generating a reference for determining the likelihood of response of a patient, suffering from a disease, towards immunoglobulin therapy comprising the steps of a) providing samples of a sufficient number of individuals, in particular at least 10 individuals, the samples containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individuals; b) determination of values of immune parameters which are either static, such as leukocyte subpopulations and cytokine-level in the plasma or functional, like gene expression and cytokine release after lipopolysaccharide (LPS) and / or IVIG stimulation ex vivo; c) the determined values derived from immune parameters of the samples of the individuals are ordered in quartiles and the values belonging to the 1. quartile, values distributed at the low end of the corresponding parameter, are set to “−1”, whereas values distributed in the 4. quartile are set to “+1” for an individual LDA-score calculation and values in between are set to “0”; d) genotyping of at least two of the polynucleotides selected from the group consisting of MTM1, EIF3E, COPS8, ADAMTSL1, CXXC4, RSPO2, OR9Q1, ADAMTS9, KLHDC8A and PRDM9, in the samples of the individuals and awarding the value of 0 for specific homozygous SNP combinations (SNP—Single Nucleotide Polymorphism), which indicates that the blood sample stems from a person which will respond to immunoglobulin (IG) treatment, while awarding the value of 1 for SNP combinations not meeting that criteria, which indicates that the blood sample stems from a person which will not respond to immunoglobulin treatment; e) combining the results of genotyping with results of immuno parameter determination in the calculation of an individual LDA-score (LDA—Linar Discriminant Analysis); f) combining a multiplicity of individual LDA-scores to create a reference Responder Score, which allows discrimination between responders and non-responders. The method can be employed for determining the likelihood of response of a patient, suffering from a disease, towards immunoglobulin therapy.
Owner:OCTAPHARMA +1

Tri-substituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis

The present invention relates to tri-substituted glycerol compounds according to formula (I) as described herein for use in the treatment of clinically isolated syndrome, relapsing remitting multiple sclerosis (RR-MS) and / or secondary progressive multiple sclerosis (SP-MS). The tri-substituted glycerol compounds according to formula (I) as described herein may also be used for the treatment of multiple sclerosis patients not adequately responding to interferon therapy. The present invention also relates to a tri-substituted glycerol compound as described herein, for use as a medicament, wherein the tri-substituted glycerol compound is administered in combination with at least one further pharmaceutically active compound.
Owner:ALPHAPTOSE +1

Cladribine regimen for treating multiple sclerosis

InactiveCN101090726AWeakening of pathological processesReduced pathological processOrganic active ingredientsNervous disorderRegimenPharmaceutical formulation
The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Owner:MERCK SERONO SA

Diagnostic or predictor of relapsing remitting multiple sclerosis

Provided herein is a method of detecting or predicting a relapse of multiple sclerosis in an individual afflicted with a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not afflicted with the form of multiple sclerosis and patients' own baseline values. Also provided herein is a method of treating an individual afflicted with multiple sclerosis, who is experiencing a relapse or predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or anti-coagulation compound effective to alleviate the symptom of multiple sclerosis.
Owner:DIGNITY HEALTH

Assay and method for predicting therapeutic efficacy of immunoglobulin therapy in individual patients with relapsing remitting multiple sclerosis (rr-ms)

A method for generating a reference for determining the likelihood of response of a patient, suffering from a disease, towards immunoglobulin therapy comprising the steps ofa) providing samples of a sufficient number of individuals, in particular at least 10 individuals, the samples containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individuals;b) determination of values of immune parameters which are either static, such as leukocyte subpopulations and cytokine-level in the plasma or functional, like gene expression and cytokine release after lipopolysaccharide (LPS) and / or IVIG stimulation ex vivo;c) the determined values derived from immune parameters of the samples of the individuals are ordered in quartiles and the values belonging to the 1. quartile, values distributed at the low end of the corresponding parameter, are set to “−1”, whereas values distributed in the 4. quartile are set to “+1” for an individual LDA-score calculation and values in between are set to “0”;d) genotyping of at least two of the polynucleotides selected from the group consisting of MTM1, EIF3E, COPS8, ADAMTSL1, CXXC4, RSPO2, OR9Q1, ADAMTS9, KLHDC8A and PRDM9, in the samples of the individuals and awarding the value of 0 for specific homozygous SNP combinations (SNP—Single Nucleotide Polymorphism), which indicates that the blood sample stems from a person which will respond to immunoglobulin (IG) treatment, while awarding the value of 1 for SNP combinations not meeting that criteria, which indicates that the blood sample stems from a person which will not respond to immunoglobulin treatment;e) combining the results of genotyping with results of immuno parameter determination in the calculation of an individual LDA-score (LDA—Linar Discriminant Analysis);f) combining a multiplicity of individual LDA-scores to create a reference Responder Score, which allows discrimination between responders and non-responders.The method can be employed for determining the likelihood of response of a patient, suffering from a disease, towards immunoglobulin therapy.
Owner:OCTAPHARMA +1

Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

InactiveUS20160074378A1Reducing ambulatory deteriorationHigh baseline disability scoreBiocideNervous disorderLaquinimodHuman patient
This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.
Owner:TEVA PHARMA IND LTD

Traditional Chinese medicine for multiple sclerosis

The invention relates to the field of medicine recipes, in particular to traditional Chinese medicine for multiple sclerosis. The traditional Chinese medicine is characterized by comprising the following active ingredients in parts by weight: 3-6 parts of caulis sinomenii, 4-6 parts of swertia mileensis, 3-7 parts of feather cockscomb seed, 4-6 parts of trametes versicolor, 4-6 parts of remote lemongrass herb, 2-4 parts of aplotaxis auriculata, 6-9 parts of glabrous sarcandra herb, 2-5 parts of radix saposhnikoviae, 5-7 parts of concha haliotidis, 2-5 parts of grassleaf sweelflag rhizome, 3-5 parts of chlorite schist, 3-5 parts of amethyst, 4-6 parts of radix ranunculi ternati, 1-2 parts of frankincense, 1-2 parts of scorpion, 2-5 parts of rhizoma cibotii, 2-4 parts of puncturevine, 2-4 parts of alisma, 2-5 parts of epimedium, 3-6 parts of radix semiaquilegiae, 2-4 parts of concretio silicea bambusae, 2-4 parts of cassia twig, 3-5 parts of fructus broussonetiae, 2-4 parts of longstamen onion bulb, 2-4 parts of stiff silkworm, and 2-4 parts of fried rhizoma arisaematis. The 26 active ingredients are soaked in water, and residues are removed after boiling to obtain a filter liquor. The traditional Chinese medicine for multiple sclerosis has the efficiencies of tonifying and replenishing liver and kidney, dredging stagnating, reducing phlegm, nourishing yin and blood, replenishing qi, strengthening the spleen, reducing fever, drying moistening, detoxicating, eliminating evil, draining dampness, dissolving turbidity, blending yin and yang, reinforcing the vital essence and strengthening the primordial qi, and is effective to relapsing-remitting, secondary progressive, primary progressive, and progressive-relapsing courses of disease.
Owner:宋春雨

Marker of Diagnosis and Prognosis in Multiple Sclerosis

The present invention provides a method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse. In the method, measuring the level of Response Gene to Complement (RGC)-32 is measured in the individual, where a significantly lower level of RGC-32 therein indicates that the individual will have or is having a relapse of multiple sclerosis.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

Diagnosis and Prognosis of Multiple Sclerosis

The present invention provides a method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse or respond to treatment for MS. A ratio of mRNA levels of Response Gene to Complement-32, FasL or IL-21 to L13 determined for an individual provides a normalized level which is compared to a cut-off value. A normalized level of Response Gene to Complement-32 greater than 2.52, a normalized level of FasL greater than 85.4 and a normalized level of IL-21 less than 11.9, respectively, indicates the individual will have or is having a relapse of multiple sclerosis. Also provided are methods for determining whether an individual will respond positively or is responding positively to glatiramer treatment and whether the individual is in a period of stable disease or is not at risk for relapse of multiple sclerosis by comparing normalized levels with the respective cut-off levels.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products